Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award

Published on by Top Pharmaceutical

Dr. Mohammad Awlad Mohammad | Oncology Pharmaceuticals | Research Excellence Award

Al-Quds University | Palestine

Dr. Mohammad Awlad Mohammad is a medical doctor and emerging researcher affiliated with the Faculty of Medicine at Al-Quds University, specializing in clinical medicine and translational research. He completed his medical degree with a strong academic record, complemented by advanced training in scientific writing, systematic reviews, and research ethics. His clinical experience includes surgical electives and pathology observerships, where he developed practical competencies in operative assistance, diagnostic workflows, and patient-centered care. Actively engaged in research, his work focuses on clinical case studies, oncology disparities, neurological therapeutics, and evidence-based analysis, contributing as both first and co-author to peer-reviewed publications, including studies on acute appendicitis atypical presentation and thoracic oncology disparities, alongside ongoing projects in multiple sclerosis and GLP-1 receptor agonists. He has demonstrated leadership through participation in research camps and academic collaborations, strengthening interdisciplinary inquiry. His certifications in Basic and Advanced Cardiac Life Support and research training programs reflect a commitment to clinical excellence and scientific integrity, positioning him as a promising contributor to advancing medical research and practice.

View ORCID Profile

 


Top Featured Publications

 

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Fenghua Wu | Oncology Pharmaceuticals | Best Researcher Award

Mrs. Fenghua Wu at Hubei university of chinese medcine, China.

Mrs. Fenghua Wu is a distinguished researcher and educator with a doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🎓. She specializes in physiology and oncology, focusing on the tumor microenvironment and tumor immunology 🔬. Her groundbreaking research explores the regulatory mechanisms of natural and traditional Chinese medicines in cancer treatment 🌿. As a principal investigator for the National Natural Science Foundation of China, she has published extensively in SCI-indexed journals 📚. Honored as a “Teaching Expert” and COVID-19 frontline contributor 🏅, she also serves as a Guest Editor for Frontiers in Immunology.

Publication Profile 

Scopus

Education

Mrs. Fenghua Wu earned her doctoral degree from Tongji Medical College, Huazhong University of Science and Technology 🏥. She currently teaches physiology and is actively engaged in oncology research 🔬 at her institution. Her work focuses on exploring cancer biology and its treatment mechanisms. As a leading scientist, she has served as the principal investigator for prestigious projects funded by the National Natural Science Foundation of China 🇨🇳. Her academic dedication and scientific contributions reflect her commitment to advancing knowledge in the field of cancer research and education.

Professional Memberships

Mrs. Fenghua Wu is a proud member of the Chinese Anti-Cancer Association (CACA) 🧬, a prestigious national organization committed to advancing cancer research, treatment, and public health awareness in China 🇨🇳. Her affiliation with CACA underscores her dedication to the oncology field and her active participation in collaborative efforts aimed at combating cancer through scientific innovation and knowledge exchange 🔬. As part of this professional body, she stays connected with leading experts, contributes to cancer-related initiatives, and continuously enhances her expertise to benefit patients and students alike.

Research Focus 

Mrs. Fenghua Wu’s research focus lies at the intersection of tumor immunology, traditional Chinese medicine, and molecular oncology 🧬. She explores how natural compounds—such as dihydroartemisinin and capsaicin—can modulate immune responses and inhibit cancer progression, particularly in breast cancer and tongue squamous cell carcinoma (TSCC) 🎯. Her studies often center on critical pathways like TNF-α, PI3K/AKT/mTOR, and TGF-β1, highlighting her commitment to advancing immunotherapy and targeted therapies 🧪. Her category of research can be broadly classified under Cancer Pharmacology, Immuno-Oncology, and Natural Product-Based Therapeutics.

Publication Top Notes

  • Dihydroartemisinin restrains angiogenesis through the TNF-α pathway to enhance the efficacy of anti-PD-1 immunotherapy in breast cancer
  • Capsaicin combined with cisplatin inhibits TGF-β1-induced EMT and TSCC cells migration via the Claudin-1/PI3K/AKT/mTOR signaling pathway

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Published on by Top Pharmaceutical

José Leite | Drug Discovery and Development | Innovator in Pharmaceutical Research Award

Dr. José Leite, Universidade de Brasília – UnB, Brazil

Dr. José Roberto Leite is a Brazilian biochemist and molecular biologist with a PhD from the University of Brasília 🇧🇷 and postdoctoral training at EMBRAPA and the University of Porto 🇵🇹. He is an Associate Professor at UnB’s Faculty of Medicine and Visiting Researcher at i3S. 🧪 As co-founder of People&Science, he works on biotechnology, nanobiotech, and bioactive peptides for health and environment 🌿. With 200+ international publications 📚, patents under development 💡, and global collaborations 🌍, he bridges biodiversity and innovation. Dr. Leite also serves as Associate Editor of the Journal of Global Innovation.

Publication Profile

Google Scholar

Education

Dr. José Roberto Leite earned his PhD in Biological Sciences (Biochemistry/Molecular Biology) from the University of Brasília 🇧🇷 and completed postdoctoral training at EMBRAPA and the University of Porto (REQUIMTE) 🇵🇹. He serves as an Associate Professor at UnB’s Faculty of Medicine and is a Visiting Researcher at i3S 🧬. He coordinated graduate programs at UFPI and UnB and founded the Biotec/UFPI research group 🧑‍🔬. As co-founder of People&Science, he leads cutting-edge work in biotechnology, nanobiotechnology, and bioprospecting for health and the environment 🌱. He is also Associate Editor of the Journal of Global Innovation 📘 and promotes international collaboration.

Professional Memberships

Dr. José Roberto Leite is actively engaged in Brazil’s leading scientific communities and holds esteemed memberships in the Brazilian Society for Biochemistry and Molecular Biology 🧪 and the Brazilian Society of Biotechnology 🧬, reflecting his deep commitment to advancing life sciences and innovation. In addition, he plays a key editorial role 📖 in the Journal of Global Innovation (JGI), contributing to the dissemination of cutting-edge research and fostering interdisciplinary collaboration 🌐. His involvement in these professional circles underscores his dedication to scientific excellence, knowledge sharing, and the promotion of impactful biotechnology and molecular biology initiatives across Brazil and beyond.

Research Focus

Dr. José Roberto Leite focuses on cutting-edge research in biotechnology, nanobiotechnology, and natural product-based drug discovery 🌱. His work spans the development of bioactive peptides 🧬, antimicrobial and anticancer compounds 💊, and innovative drug delivery systems 🚀. He explores biodiversity to identify novel molecules from amphibians 🐸, plants 🌿, and marine life 🌊 for therapeutic and diagnostic applications. Dr. Leite also contributes to the advancement of biosensors, nutraceuticals, and functional biomaterials. His interdisciplinary research bridges biochemistry, molecular biology, and pharmacology, driving translational science for global health and environmental impact.

Publication Top Notes

Dermaseptins from Phyllomedusa oreades andPhyllomedusa distincta: ANTI-TRYPANOSOMA CRUZI ACTIVITY WITHOUT CYTOTOXICITY TO MAMMALIAN CELLS

Phylloseptins: a novel class of anti-bacterial and anti-protozoan peptides from the Phyllomedusa genus

Transtornos de ansiedade e exercício físico

Identification of a cowpea γ‐thionin with bactericidal activity

Antimicrobial activity of the bufadienolides marinobufagin and telocinobufagin isolated as major components from skin secretion of the toad Bufo rubescens

Medical students, spirituality and religiosity-results from the multicenter study SBRAME

Anti-inflammatory and Antinociceptive Activity of Epiisopiloturine, an Imidazole Alkaloid Isolated from Pilocarpus microphyllus

Novel dermaseptins from Phyllomedusa hypochondrialis (Amphibia)

Development and antibacterial activity of cashew gum-based silver nanoparticles

Antinociceptive activity of the monoterpene α-phellandrene in rodents: possible mechanisms of action

The NMR-derived solution structure of a new cationic antimicrobial peptide from the skin secretion of the anuran Hyla punctata

Antidiarrheal activity of cashew GUM, a complex heteropolysaccharide extracted from exudate of Anacardium occidentale L. in rodents

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Published on by Top Pharmaceutical

Natalia Marina CARDILLO | Drug Discovery and Development | Best Researcher Award

Dr. Natalia Marina CARDILLO, USDA-ARS-WSU, United States

Dr. Natalia Marina Cardillo is a distinguished veterinary scientist from Argentina with a Ph.D. in Veterinary Sciences, specializing in parasitology and public health 🧫. Currently a Postdoctoral Research Associate at Washington State University 🇺🇸, she focuses on chemotherapeutic strategies for bovine babesiosis. With over two decades of academic and research excellence across UBA, CONICET, INTA, and USDA, she has led groundbreaking projects on zoonoses, antiparasitic drug resistance, and diagnostics. 🧬 Her contributions span teaching, diagnostics, and pharmaceutical clinical trials in veterinary medicine, earning her global recognition and prestigious fellowships.

Publication Profile

Google Scholar

Education

Dr. Natalia Marina Cardillo began her academic path with a Doctor of Veterinary Medicine degree (1997–2004) from the Universidad de Buenos Aires, Argentina, specializing in Public Health 🐕‍🦺🩺. She furthered her expertise by completing a Ph.D. in Veterinary Sciences with a focus on Parasitology and Public Health (2006–2012), earning the prestigious “summa cum laude” distinction for her thesis on Toxocara cati in murine models 🧬🧫. To complement her academic and research proficiency, she pursued a University Teaching Major in Veterinary and Biological Sciences (2014–2016), strengthening her role as an educator and mentor 📚👩‍🏫.

Experience

Dr. Natalia Marina Cardillo has led a distinguished career in parasitology, veterinary microbiology, and public health. Currently a Postdoctoral Research Associate at Washington State University 🐄💊, she focuses on developing novel treatments for bovine babesiosis. Previously, she served as Senior and Principal Scientist at CONICET-INTA 🇦🇷, leading studies on zoonotic parasitic diseases. With over two decades of academic roles at the Universidad de Buenos Aires 👩‍🏫🧫, she also contributed significantly to diagnostics, laboratory accreditation, and veterinary clinical trials. As founder of ALIANZA InVet 🧬🐕, she has pioneered ethical animal research and advanced pharmaceutical testing across Argentina.

Awards

Dr. Natalia Marina Cardillo has received numerous prestigious honors throughout her career. From 2023 to 2025, she was awarded a competitive Postdoctoral Fellowship by the USDA at Washington State University 🇺🇸🔬. In 2018, she won the NAVES entrepreneurship competition by Universidad Austral’s IAE Business School for her CRO-VET project 🏅💼. Her academic excellence was recognized early with a Ph.D. fellowship (2005–2010) in Public Health Veterinary Medicine and a Scientific Research Scholarship (2000–2002) in Parasitology at Universidad de Buenos Aires 🇦🇷📘—highlighting her dedication to veterinary science and innovation.

Research Focus

Dr. Natalia Marina Cardillo’s research is rooted in veterinary parasitology, with a strong emphasis on zoonotic diseases, public health, and epidemiology 🐛🧫🌍. Her work investigates parasites like Toxocara cati, Trichinella spp., and Aelurostrongylus abstrusus, exploring their life cycles, transmission, and pathology in animal hosts and their public health implications 💉📊. She also focuses on developing chemotherapeutic treatments for diseases such as bovine babesiosis, integrating pharmacology, immunology, and molecular diagnostics 🧬💊. Her interdisciplinary research contributes significantly to One Health, bridging human, animal, and environmental health.

Publication Top Notes

Prevalence of Toxocara cati and other parasites in cats’ faeces collected from the open spaces of public institutions: Buenos Aires, Argentina

Trichinella infection in wild animals from endemic regions of Argentina

Experimental Infection with Toxocara cati in BALB/c Mice, Migratory Behaviour and Pathological Changes

Prevalence of canine dirofilariosis in the city of Buenos Aires and its outskirts (Argentina)

Evaluation of the risk of transmission of Trichinella in pork production systems in Argentina

First report of Toxocara cati in the domestic land snail Rumina decollata

Soil contamination with eggs of Toxocara species in public parks of Karaj, Iran

Clinical, haematological, biochemical and economic impacts of Trichinella spiralis infection in pigs

First report of Aelurostrongylus abstrusus in domestic land snail Rumina decollata, in the Autonomous city of Buenos Aires

EXPERIMENTAL INFECTION WITH Toxocara cati IN PIGS: MIGRATORY PATTERN AND PATHOLOGICAL RESPONSE IN EARLY PHASE

Nuevos aportes al conocimiento de Trichinella y trichinellosis

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Published on by Top Pharmaceutical

Takuma Hayashi | Oncology Pharmaceuticals | Best Researcher Award

Prof. Dr. Takuma Hayashi, National Hospital Organization Kyoto Medical Center, Japan

Prof. Dr. Takuma Hayashi is a renowned Japanese physician-scientist specializing in gynecologic oncology. 🎓 He earned his PhD from the University of Tokyo and trained at MIT’s Whitehead Institute 🧠, contributing to Nobel-linked research. Currently a professor at Shinshu University and Section Head at Kyoto Medical Center 🏥, his groundbreaking work on uterine leiomyosarcoma (LMS) identified LMP2 deficiency as a key biomarker 🔎. Through precision medicine and genomic profiling 🧬, his research has significantly advanced diagnostics and treatment strategies for LMS. With over 30 years of funded research, Dr. Hayashi is globally recognized for revolutionizing women’s cancer care.

Publication Profile

Scopus

Education

Prof. Dr. Takuma Hayashi is a distinguished physician-scientist known for bridging fundamental cancer research with clinical applications. 👨‍⚕️🔬 He is a Professor at Shinshu University Graduate School of Medicine and Section Head at Japan’s National Hospital Organization Kyoto Medical Center. 🎓🏥 Dr. Hayashi earned his PhD from the University of Tokyo and completed postdoctoral training at MIT’s Whitehead Institute under Dr. Rick A. Young. 🎓🇯🇵🇺🇸 He contributed to Nobel Prize-linked AIDS vaccine research with Dr. David Baltimore. With over 30 years of NIH and JSPS funding, his work focuses on molecular research in uterine leiomyosarcoma and ovarian cancer, collaborating with Nobel Laureate Dr. Susumu Tonegawa.

Experience

Prof. Dr. Takuma Hayashi has pioneered precision medicine breakthroughs in uterine leiomyosarcoma (LMS) treatment. 🧬💉 His team used cancer genome panel testing to tailor therapies based on each tumor’s unique genetics. For example, immunotherapy with pembrolizumab led to significant tumor regression, while targeted treatment with pazopanib stabilized disease for months. 🎯💊 Dr. Hayashi’s background from the University of Tokyo and MIT supports his innovative approach. 🚀 His ongoing goals include developing diagnostics, launching clinical trials, expanding global collaboration, and improving patient access to genomic profiling. 🌍💡 His work offers new hope for women facing this aggressive cancer.

Research Focus

Prof. Dr. Takuma Hayashi’s research primarily focuses on molecular oncology and infectious diseases, particularly cancer biomarkers and viral infections. 🧬🔬 His work on uterine leiomyosarcoma involves discovering key diagnostic biomarkers like LMP2 to improve early detection and treatment strategies in aggressive cancers. 🩺🎗️ Additionally, Dr. Hayashi explores infectious diseases such as avian influenza and COVID-19, emphasizing the One Health approach to prevent viral spread between animals and humans. 🦠🌍 His interdisciplinary research bridges cancer biology, immunology, and public health, aiming to develop precision medicine therapies and enhance global disease control efforts.

Publication Top Notes

THE ROLE OF LIVE BIRD MARKETS SHOULD BE EMPHASIZED IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA INFECTIONS

THE IMPORTANCE OF ONE HEALTH IN PREVENTING THE SPREAD OF HIGHLY PATHOGENIC AVIAN INFLUENZA/H5N1

Efficacy and Tolerability of Olaparib Plus Paclitaxel in Patients with Gastric Cancer Associated with Hereditary Breast and Ovarian Cancer

DEVELOPMENT OF ENDOSALPINGIOSIS IN PATIENTS WITH A HISTORY OF BREAST CANCER

High Transferability of Neutralizing Antibodies against SARS-CoV-2 to Umbilical Cord Blood in Pregnant Women Vaccinated with BNT162b2 XBB.1.5: A Retrospective Cohort Study

POTENTIAL DIAGNOSTIC BIOMARKERS FOR HUMAN MESENCHYMAL TUMORS, ESPECIALLY LMP2/Β1I AND CYCLIN E1/MIB1 DIFFERENTIAL EXPRESSION: PRUM-IBIO STUDY

Assoc Prof Dr. Sanli Jin| Oncology Pharmaceuticals |Best Researcher Award

Published on by Top Pharmaceutical

Assoc Prof Dr. Sanli Jin|Oncology Pharmaceuticals|Best Researcher Award

Assoc Prof Dr. Sanli Jin at Peking University School of Nursing,China

PROFILE  

scopus

Early Academic Pursuits 🎓

Sanli Jin embarked on her academic journey at Peking University, one of the most prestigious institutions in China. After joining the School of Nursing in 2004, she pursued her doctoral degree with a specific focus on oncology and nutrition nursing, surgical nursing, and nursing simulation. Her early years of academic training at Peking University provided her with a strong foundation in both theoretical knowledge and practical skills. This combination of educational rigor and practical exposure positioned her to become a leader in the field of nursing education in China.

Professional Endeavors 👩‍🏫

Since completing her doctoral studies, Sanli Jin has been an integral member of the School of Nursing at Peking University, where she serves as an Associate Professor. Her professional work spans various aspects of nursing education, including her involvement in the development and promotion of artificial intelligence-assisted learning methods. Sanli’s teaching excellence has been acknowledged through her role in managing and leading virtual and in-person simulation projects. These projects aim to improve the critical thinking and practical skills of undergraduate nursing students, setting a new standard for nursing education across China.

Sanli has also been actively involved in several key research initiatives, including the development of multimodal teaching methods for diseases of the urinary system and an in-depth study of nutrition-related symptoms in cancer patients undergoing radiotherapy. Through these contributions, she has gained recognition as a leading voice in nursing research and innovation, not only in China but also internationally.

Research and Contributions 📚

Sanli Jin’s research focuses primarily on three main areas: oncology and nutrition nursing, surgical nursing, and nursing simulation. Her contributions in these areas have significantly influenced both clinical practice and education. A key component of her research involves exploring the relationship between nutritional status and patient outcomes in oncology, particularly for patients with head and neck cancers. Her work in this domain has provided valuable insights into managing the complex nutritional needs of cancer patients, and she has earned awards for her research contributions, such as the Second Prize of the Beijing Nursing Society Science and Technology Award.

Another notable aspect of her work is in nursing simulation. Sanli has designed numerous simulation scenarios aimed at enhancing student learning, with her work receiving accolades such as the First Prize in the Case Group of the “Ninth Peking University Innovative Teaching and Learning Application Competition.” These contributions highlight her commitment to improving the quality of nursing education and equipping future nurses with the tools they need to succeed in complex clinical environments.

Accolades and Recognition 🏆

Over her career, Sanli Jin has been the recipient of multiple awards recognizing both her teaching excellence and her contributions to nursing research. Among her most notable accolades are:

  • National First Class Undergraduate Online Course: An award that highlights her contributions to the development of innovative, high-quality online nursing education.
  • Second Prize of the Beijing Nursing Society Science and Technology Award (Technical Achievement Award): Recognizing her work in the nutritional management of cancer patients.
  • Teaching Excellence Award from Peking University Health Science Center: A testament to her commitment to nursing education and student development.

In addition to these awards, Sanli has published nearly 100 papers in prominent national and international journals, further cementing her reputation as a researcher. Her work has garnered 389 citations and earned her an h-index of 11, showcasing the impact and influence of her research within the academic community.

Impact and Influence 🌍

Sanli Jin’s influence extends beyond her individual achievements in research and education. Her work in oncology nursing has had a profound impact on improving patient care, particularly for cancer patients undergoing radiotherapy. Through her research on nutrition and cancer, she has contributed to a better understanding of how dietary interventions can improve patient outcomes. Her efforts have also advanced simulation-based learning in nursing, bridging the gap between theoretical knowledge and practical skills for future generations of nurses.

Her leadership extends to various professional organizations as well. As a member of the MDT Professional Committee for Head and Neck Tumors and the Youth Committee for Cancer Rehabilitation and Nursing, Sanli actively collaborates with other professionals to push the boundaries of nursing science. These memberships allow her to continue influencing the field of oncology nursing, contributing to new standards and best practices.

Legacy and Future Contributions 🌱

Sanli Jin’s contributions have set a strong foundation for the future of nursing in China, particularly in the fields of oncology, nutrition, and nursing simulation. As a pioneer in incorporating artificial intelligence into nursing education, she has paved the way for future generations to embrace technology as a tool for enhancing both learning and patient care. Her ongoing research projects, such as the exploration of virtual simulation’s impact on nursing education, position her at the forefront of innovative teaching methods.

Her legacy is not just one of research and education but also of mentorship and leadership. Sanli has played a key role in nurturing the next generation of nurses and healthcare professionals, instilling in them the values of critical thinking, innovation, and compassion. Her commitment to advancing the field of nursing through both educational initiatives and patient care improvements ensures that her influence will continue to resonate for years to come.

Conclusion 📝

Sanli Jin’s academic and professional journey reflects a deep commitment to improving both nursing education and patient care. From her early academic pursuits to her innovative contributions in research and teaching, she has become a recognized leader in the field of nursing. Her work has not only earned her multiple prestigious awards but has also left a lasting impact on both her students and the broader nursing community. As she continues to explore new avenues of research and education, her legacy as a visionary in nursing will continue to grow, shaping the future of healthcare in China and beyond.

🎓Publication 

Evaluation of the combination of virtual simulation and in-person simulation among undergraduate nursing students: A mixed methods study

  • Authors   : Han, F., Jin, S.
  • Journal    :Nurse Education in Practice
  • Year         :2024

Body composition and dietary intake in patients with head and neck cancer during radiotherapy: A longitudinal study

  • Authors   :Zhuang, B., Zhang, L., Wang, Y., … Jin, S., Lu, Q.
  • Journal    :BMJ Supportive and Palliative Care,
  • Year         :2023

Predictive effect of pretreatment nutritional risk and GLIM-defined malnutrition on the nutrition impact symptom clusters in patients with head and neck cancer undergoing radiotherapy

  • Authors   : Wang, Y., Zhang, L., Zhang, T., … Sun, Y., Lu, Q.
  • Journal    :Head and Neck
  • Year         :2023

Routine replacement versus replacement as clinical indicated of peripheral intravenous catheters: A multisite randomised controlled trial

  • Authors   : Li, J., Ding, Y., Lu, Q., … Lyu, Y., Lin, F.
  • Journal    :Journal of Clinical Nursing,
  • Year         :2023.

Association between body composition and survival in head and neck cancer patients undergoing radiotherapy

  • Authors   : Zhuang, B., Xiao, S., Zhang, L., … Sun, Y., Lu, Q.
  • Journal    :Head and Neck,
  • Year         :2022

Dr.Long Pang |Oncology Pharmaceuticals| Best Researcher Award-1332

Published on by Top Pharmaceutical

Dr.Long Pang|Oncology Pharmaceuticals |Best Researcher Award|

Dr.Long Pang at Xi’an Medical University, China

PROFILE  

scopus

Early Academic Pursuits 📚

Long Pang was born in Gansu, China, where he developed an early passion for science and innovation. His academic journey began with a focus on veterinary science, where he pursued a Master of Science (M.S.) degree at Northwest Agricultural and Forestry University in Yangling, Shaanxi, China. Completing his M.S. in July 2012, Pang demonstrated an exceptional commitment to his studies and research in veterinary science, laying the groundwork for his future endeavors in animal biotechnology. In August 2012, he advanced his academic career by enrolling in a Ph.D. program at the same university. During his Ph.D. studies, he specialized in Animal Biotechnology, a field that encompasses the use of biotechnological tools for the improvement of animal health and productivity. He completed his Ph.D. in July 2016, marking the beginning of a promising career in biomedical research.

Professional Endeavors 🏢

After earning his Ph.D., Long Pang joined Xi’an Medical University as an Associate Professor in the School of Basic Medical Science. His professional career is distinguished by his innovative research in the areas of microfluidics and single-cell analysis. At Xi’an Medical University, Pang quickly established himself as a leading researcher, focusing on the development of microfluidic chips and their applications in single-cell analysis and organ-on-a-chip technology. His work has been instrumental in advancing the understanding of cellular mechanics and tumor microenvironments, contributing significantly to the fields of biomedical engineering and cancer research.

Contributions and Research Focus 🔬

Long Pang’s research primarily revolves around microfluidics-based single-cell analysis and organ-on-a-chip technologies. His work has led to the development of innovative microfluidic devices that allow for the manipulation and analysis of single cells in a highly controlled environment. These devices have broad applications in cancer research, particularly in studying tumor microenvironments and the behavior of cancer stem cells. One of his significant contributions includes the development of a microfluidic chip for glioma stem cell sorting and single-cell-derived tumor sphere assays. This research has provided valuable insights into the formation of tumor spheres and the role of the tumor microenvironment in cancer progression.

Pang has also been involved in projects aimed at integrating microfluidic platforms with other technologies to enhance the precision and efficiency of single-cell analysis. His research has been supported by several prestigious grants, including those from the National Science Foundation of China and the Fundamental Research Foundation of Xi’an Medical University. Notably, he has led projects such as the study of heterotypic single-cell-derived tumor-sphere formation using an integrated microfluidics platform, which has garnered significant attention and funding.

Accolades and Recognition 🏆

Long Pang’s contributions to the field of biomedical research have been widely recognized. His work has resulted in over 21 publications in high-impact journals, including TRAC-Trends in Analytical Chemistry, Analytical Chemistry, and Sensors & Actuators B: Chemical. He has also authored a chapter in the Handbook of Single-Cell Technologies, published by Springer, highlighting his expertise in digital microfluidics for single-cell manipulation and analysis. In addition to his publications, Pang has been granted two Chinese patents related to his innovations in microfluidic technology, further establishing his reputation as a leading researcher in his field.

Pang’s achievements have also been acknowledged through various editorial appointments. He has served as a Youth Editorial Board Member of Glioma and the E-Journal of Translational Medicine, where he has contributed to the advancement of research dissemination and knowledge sharing in the scientific community. His contributions to the academic community extend beyond research, as he is an active member of several professional organizations, including the Shaanxi Pharmacology Association, the Chinese Society of Micro-Nano Technology (CSMNT), and the Chinese Chemistry Society (CCS).

Impact and Influence 🌍

The impact of Long Pang’s research extends beyond academia. His work on microfluidic devices has the potential to revolutionize the way single-cell analysis is conducted, offering new tools for researchers and clinicians in the diagnosis and treatment of diseases, particularly cancer. His contributions to the development of organ-on-a-chip technology are also significant, providing a platform for more accurate and efficient drug testing, which could lead to more effective treatments for various diseases.

Pang’s research has influenced a new generation of scientists and engineers, inspiring them to explore the possibilities of microfluidics and its applications in biomedical research. His collaborations with other leading researchers and institutions, both in China and internationally, have further expanded the reach of his work, fostering innovation and knowledge exchange in the global scientific community.

Legacy and Future Contributions 🚀

Long Pang’s legacy in the field of biomedical research is characterized by his innovative approach to solving complex problems in cell biology and medicine. His contributions to the development of microfluidic technology and single-cell analysis tools have set new standards in the field, paving the way for future research and innovation. As he continues his work at Xi’an Medical University, Pang remains committed to advancing the frontiers of biomedical engineering, with a focus on developing new technologies that can improve human health and well-being.

Looking to the future, Long Pang’s ongoing research projects, such as the construction of a 3D microenvironment for single-cell level tumor cells, promise to yield further breakthroughs in our understanding of cancer and other diseases. His work is likely to continue to influence the field for years to come, as he mentors the next generation of researchers and contributes to the global effort to improve healthcare through technological innovation.

🎓Publication 

Tumor microenvironment-derived exosomes-assisted single-cell-derived tumor-sphere formation and drug-resistance by a microfluidic system

Construction of multiple concentration gradients for single-cell level drug screening

Droplets microfluidics platform—A tool for single cell research

Microfluidics-Based Single-Cell Research for Intercellular Interaction

Digital Microfluidics for Single Cell Manipulation and Analysis

  • Authors   :Pang, L., Ding, J., Fan, S.-K.
  • Journal    :Handbook of Single-Cell Technologies
  • Year         :2021